curacle co.,ltd. (KOSDAQ: A365270)
Health Care · Biotechnology · KR
₩10,840.00
-11.29% today · +153.9% 1Y
curacle co.,ltd. (KOSDAQ: A365270) operates in the Biotechnology industry within the Health Care sector. The company is valued at $166.63M.
Over the last twelve months the share price has gained 153.9%, trading between 3.60K and 20.75K.
Tweenvest scores curacle co.,ltd. across four factors: quality 31/100, value 54/100. Its strongest factor is value.
A365270 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $166.63M
- Revenue (TTM)
- $693.78K
- P/E
- —
- EPS
- -947.23
- Dividend yield
- —
- Beta (5Y)
- 2.10
- 52-week high
- ₩20,750.00
- 52-week low
- ₩3,600.00
- Avg volume (3M)
- —
- Shares outstanding
- 21.30M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.96 | +0.06% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €898.00 | +2.14% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.51 | -0.83% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.